Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Hoth Therapeutics Inc (HOTH)

Hoth Therapeutics Inc (HOTH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 32,378
  • Shares Outstanding, K 13,435
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,700 K
  • 60-Month Beta 0.93
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.14
  • Number of Estimates 1
  • High Estimate -0.14
  • Low Estimate -0.14
  • Prior Year -0.13
  • Growth Rate Est. (year over year) -7.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.14 +9.81%
on 09/09/20
2.77 -15.16%
on 08/19/20
-0.43 (-15.47%)
since 08/18/20
3-Month
2.14 +9.81%
on 09/09/20
3.89 -39.59%
on 07/17/20
-0.29 (-10.98%)
since 06/18/20
52-Week
2.14 +9.81%
on 09/09/20
7.25 -67.59%
on 12/30/19
-2.65 (-53.00%)
since 09/18/19

Most Recent Stories

More News
Voltron Therapeutics, Inc. Executes Manufacturing Agreement with Global Pharmaceutical Contract Development and Manufacturing Organization

Voltron Therapeutics, Inc. today announced that it has executed a manufacturing agreement for its vaccine portfolio with a global pharmaceutical contract development and manufacturing organization. The...

HOTH : 2.35 (-2.49%)
Voltron Therapeutics, Inc. Announces Completion of First Small Animal Safety and Immunogenicity Study Assessing the Effect of Novel COVID-19 Vaccine, HaloVax(TM)

Voltron Therapeutics, Inc. announced today the successful completion of its previously announced first small animal safety and immunogenicity study assessing the effect of novel Covid-19 vaccine HaloVax(TM)....

HOTH : 2.35 (-2.49%)
Hoth Therapeutics' Chief Scientific Officer, Dr. Stefanie Johns, to Appear on One America News Network on Tuesday, September 1, 2020

, , 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced  Dr. , who has agreed to join Hoth and serve as its Chief Scientific Officer, is scheduled...

HOTH : 2.35 (-2.49%)
Hoth Therapeutics Appoints Stefanie Johns, Ph.D., as Chief Scientific Officer

, /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company, today announces the appointment of Stefanie Johns, Ph.D., to the position of Chief Scientific Officer, effective...

HOTH : 2.35 (-2.49%)
Hoth Therapeutics Announces Participation at Upcoming Investor Conferences in September

, /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Chief Executive Officer, Robb Knie, is scheduled to present at the following investor conferences...

HOTH : 2.35 (-2.49%)
Laidlaw Venture Partners Hosts Panel Discussion "Cutting Edge Perspectives on the Latest Developments in COVID-19 Vaccine Development Strategy"

Featuring

HOTH : 2.35 (-2.49%)
Hoth Therapeutics Provides Shareholder Update on COVID-19 Initiatives and Dermatological Therapy Pipeline

, /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today is providing shareholders with a update on its COVID-19 initiatives including vaccine and real-time,  as...

HOTH : 2.35 (-2.49%)
Hoth Therapeutic Announces That It Has Submitted its Request to Australia Ethics Board to Begin Clinical Trial of BioLexa for Atopic Dermatitis

, /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has submitted for ethics approval in for its planned Clinical study of its therapeutic...

HOTH : 2.35 (-2.49%)
Hoth Therapeutics to Participate in LD Micro's Zooming with LD, August 11th 8 AM PDT

NEW YORK, NY / ACCESSWIRE / August 10, 2020 / Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, announced today that the Company would be presenting at LD Micro's Zooming with LD on Tuesday,...

HOTH : 2.35 (-2.49%)
Hoth Therapeutics Licenses Intellectual Property to Develop Real-time, Breath-Based COVID-19 Mobile Testing Device

, /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced licensing the intellectual property rights relating to the development of a medical device that...

HOTH : 2.35 (-2.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade HOTH with:

Business Summary

Hoth Therapeutics Inc. is a development stage biopharmaceutical company. It focused on therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. The company's BioLexa(TM) Platform is a proprietary, patented drug compound platform. Hoth Therapeutics Inc. is...

See More

Key Turning Points

2nd Resistance Point 2.44
1st Resistance Point 2.40
Last Price 2.35
1st Support Level 2.31
2nd Support Level 2.26

See More

52-Week High 7.25
Fibonacci 61.8% 5.30
Fibonacci 50% 4.70
Fibonacci 38.2% 4.09
Last Price 2.35
52-Week Low 2.14

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar